Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® in US
Alembic Pharmaceuticals Limited announced the first prescription-based sale of Pivya® (pivmecillinam) tablets, an oral prescription antibiotic, following its recent commercial launch in the United States of America. Pivya® is Alembic’s first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC. The therapeutic category represents a large and stable market, accounting for approximately 30 million prescriptions annually in the US. Alembic has established an initial sales footprint across key territories in the US, with each territory focusing on high-prescribing physicians in women’s health and engaging a targeted base of prescribers. The Company plans a phased expansion of field force as prescription momentum builds, supported by targeted physician education and market access initiatives.
Key Highlights
- Alembic Pharmaceuticals reports first prescription sale of Pivya® in US
- Pivya® is Alembic’s first branded pharmaceutical product in the US
- Pivya® represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women
- Alembic has established an initial sales footprint across key territories in the US
- Company plans a phased expansion of field force as prescription momentum builds